Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

胚胎著床當天打~~Deca,可~~增加~?~成功率~~的秘密??

Loading...

Sign in or sign up now!
105 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Nov 4, 2009

胚胎著床當天打Deca,可增加成功率的秘密10.7
Gynecology and Obstetrics, Johns Hopkins Medical Institution, Baltimore, MD; Muasher Center for Fertility and IVF, Fairfax, VA


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

• Copyright
OBJECTIVE: Our goal was to assess a novel role for GnRH-agonist as a supplement in luteal phase. GnRH-agonist receptors are present in the endometrium and the ovaries. Furthermore, the corpus luteum function may improve with GnRH-agonist induced endogenous flare with pituitary hormones. In vitro, GnRH-agonists have improved mouse embryo developement. Recent studies have demonstrated improved implantation rate with the use of a single dose GnRH-agonist 6 days after oocyte retreival in an IVF cycle (Tesarik, Hum Reprod, 2006,21: 2572-9). Our objective was to evaluate the impact of a daily GnRH-agonist at the time of implantation (Days 5-7 following retreival) on IVF outcomes in antagonist cycles.


GnRH-agonist administration in the mid-luteal phase yields favorable pregnancy and implantation rates in stimulated in vitro fertilization cycles with GnRH-antagonist

Z.R. Hubayter, A. Rettberg, A. Ibrahim, H. Zacur, J. Garcia, S.J. Muasher
P-763

Article Outline

• Copyright
OBJECTIVE: Our goal was to assess a novel role for GnRH-agonist as a supplement in luteal phase. GnRH-agonist receptors are present in the endometrium and the ovaries. Furthermore, the corpus luteum function may improve with GnRH-agonist induced endogenous flare with pituitary hormones. In vitro, GnRH-agonists have improved mouse embryo developement. Recent studies have demonstrated improved implantation rate with the use of a single dose GnRH-agonist 6 days after oocyte retreival in an IVF cycle (Tesarik, Hum Reprod, 2006,21: 2572-9). Our objective was to evaluate the impact of a daily GnRH-agonist at the time of implantation (Days 5-7 following retreival) on IVF outcomes in antagonist cycles.

DESIGN: Retrospective analysis.
DESIGN: Retrospective analysis.

CONCLUSIONS: Mid luteal phase support with GnRH-agonist, around the days of implantation appears to yield favorable outcomes in IVF cycles using GnRH-antagonists for ovarian stimulation. A large randomized prospective controlled trial will need to be conducted in order to confirm these findings.

Gynecology and Obstetrics, Johns Hopkins Medical Institution, Baltimore, MD; Muasher Center for Fertility and IVF, Fairfax, VA
Supported by: None.

PII: S0015-0282(08)02718-0

doi:10.1016/j.fertnstert.2008.07.1347

© 2008 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Table 1. IVF outcome with GnRH-agonist luteal supplementation
Parameter Mean (SD)
Age (years) 34.7 (4.4)
Day 3 FSH (IU/L) 7.9 (2.2)
Peak estradiol (pg/ml)1664 (957)
Embryos transferred (n)3.0 (0.8)
Pregnancy rate / transfer55%
Implantation rate 28%
Miscarriage rate 11%

Category:

People & Blogs

Tags:

License:

Standard YouTube License

  • likes, 0 dislikes

Link to this comment:

Share to:

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more